A stable lyophilized formulation containing daptomycin

A stable lyophilized daptomycin formulation using L-arginine, inositol, dextran, meglumine, or macrogol maintains stability at room temperature, addressing the need for refrigeration and ensuring long-term storage and rapid redissolution.

JP7582205B2Active Publication Date: 2024-11-13NIPRO CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021566870
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-26
Filing Date
2020-10-29
Publication Date
2024-11-13
Estimated Expiration
2040-10-29

AI Technical Summary

Technical Problem

Daptomycin formulations require refrigeration for storage, limiting their accessibility and convenience.

Method used

A lyophilized preparation of daptomycin stabilized with L-arginine, inositol, dextran, meglumine, or macrogol, maintaining stability at room temperature.

Benefits of technology

Ensures stability and long-term storage at room temperature, with rapid redissolution and reduced generation of total related substances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582205000006
    Figure 0007582205000006
  • Figure 0007582205000001
    Figure 0007582205000001
  • Figure 0007582205000002
    Figure 0007582205000002
Patent Text Reader

Abstract

The purpose of the present invention is to provide a freeze-dried formulation that contains daptomycin and that can be stabilized enough to be stored at room temperature. A stable freeze-dried formulation comprising daptomycin and one or more stabilizers selected from L-arginine, inositol, dextran, meglumine, macrogol, and L-histidine.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to stable lyophilized formulations containing daptomycin. [Background technology]

[0002] Daptomycin is a cyclic lipopeptide antibiotic that is used to treat sepsis, infective endocarditis, deep skin infections, secondary infections in trauma, burns, and surgical wounds, and secondary infections in erosions and ulcers. Daptomycin is prescribed as an intravenous solution to treat infections caused by several gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) (Patent Document 1, etc.). Daptomycin for injection (Cubicin (registered trademark), MSD Corporation) is provided as a lyophilized powder (Non-Patent Document 1, etc.). However, it usually requires storage in a cool place at 2°C to 8°C. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Special Publication No. 2013-511557 [Non-patent literature]

[0004] [Non-Patent Document 1] Package insert for Cubicin 350mg for intravenous injection Summary of the Invention [Problem to be solved by the invention]

[0005] Under these circumstances, there is a need for a formulation containing daptomycin that is stable when stored at room temperature. An object of the present invention is to provide a freeze-dried preparation containing daptomycin that can maintain stability when stored at room temperature. [Means for solving the problem]

[0006] As a result of extensive research, the present inventors have found that the use of a specific stabilizer can stabilize a lyophilized preparation containing daptomycin to such an extent that it can be stored at room temperature. This application includes the following inventions: [1] Daptomycin and A stable freeze-dried formulation comprising one or more stabilizers selected from L-arginine, inositol, dextran, meglumine, macrogol and L-histidine. [2] The freeze-dried formulation described above, wherein the stabilizer is one or more selected from the group consisting of L-arginine, inositol and dextran. [3] The freeze-dried formulation described above, wherein the stabilizer is L-arginine. [4] The stable freeze-dried preparation described above, wherein the pH of the preparation when dissolved with water for injection is 5.5 to 7.5. Effect of the Invention

[0007] According to the present invention, it is possible to provide a freeze-dried preparation which contains daptomycin and can maintain stability when stored at room temperature. [Brief description of the drawings]

[0008] [Figure 1] 1 is a graph showing the increase in total related substances relative to the amount of L-arginine added in a daptomycin-containing lyophilized formulation of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] The daptomycin-containing lyophilized formulation of the present application is a lyophilized formulation that can maintain the stability of daptomycin even when stored at room temperature, i.e., a solid daptomycin-containing formulation for preparing a liquid formulation containing daptomycin. Daptomycin is disclosed, for example, in U.S. Pat. No. 4,537,717 and is 72 H 101 N 17 O26 It is a cyclic polypeptide antibiotic with a molecular weight of 1620.67 and a chemical formula represented by the formula: The daptomycin-containing lyophilized preparation of the present application contains one or more stabilizers selected from L-arginine, inositol, dextran, meglumine, macrogol, and L-histidine. The content of the stabilizer is, relative to the total mass of daptomycin, 3% by mass to 250% by mass, preferably 6% by mass to 200% by mass, and more preferably 10% by mass to 136% by mass. From another viewpoint, the content is, relative to the total mass of the lyophilized formulation, 1% by mass to 80% by mass, preferably 5% by mass to 70% by mass, and more preferably 10% by mass to 60% by mass. Specifically, relative to 367.5 mg of daptomycin, the content is preferably 10 mg to 800 mg, more preferably 20 mg to 600 mg, even more preferably 30 mg to 500 mg, and particularly preferably 35 mg to 500 mg. In particular, when L-arginine is contained, the amount is preferably 200 mg to 800 mg, more preferably 300 mg to 600 mg, and even more preferably 350 mg to 500 mg. When inositol is contained, the amount is preferably from 1 mg to 150 mg, more preferably from 10 mg to 100 mg, and even more preferably from 20 mg to 80 mg. When dextran is contained, the amount is preferably 10 mg to 500 mg, more preferably 50 mg to 300 mg, and even more preferably 70 mg to 250 mg. The type of dextran is not particularly limited, but dextran 40 is preferred. When meglumine is contained, the amount is preferably 10 mg to 400 mg, more preferably 30 mg to 200 mg, and even more preferably 50 mg to 150 mg. When macrogol is contained, the amount is preferably 10 mg to 500 mg, more preferably 50 mg to 300 mg, and further preferably 70 mg to 250 mg. The type of macrogol is not particularly limited, but macrogol 4000 is preferred. When L-histidine is contained, the amount is preferably 10 mg to 500 mg, more preferably 50 mg to 300 mg, and even more preferably 70 mg to 250 mg.

[0010] In addition to the above-mentioned stabilizers, the composition may further contain stabilizers known in the art. Examples of such stabilizers include those exemplified in JP-A Nos. 2004-10511, 05-306235, and JP-T No. 2001-525372. The amount of the stabilizer other than the above-mentioned stabilizers can be 0.1% by mass to 100% by mass, preferably 0.1% by mass to 99.99% by mass, based on the total mass of daptomycin.

[0011] The daptomycin-containing lyophilized formulation of the present application may contain any additives commonly used in pharmaceuticals, as necessary, including additives known in the art, such as pH adjusters, isotonicity agents, bulking agents, antioxidants, preservatives / antiseptics, carbohydrates, water-soluble polymers, hydrophilic or hydrophobic materials, gelatin, oils, etc. Examples of preservatives / antiseptics include cresol, benzyl alcohol, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, phenylethyl alcohol, methylparaben, propylparaben, thimerosal, nitric acid, and phenylmercuric acetate, but it is preferable not to include these.

[0012] The daptomycin-containing lyophilized formulation of the present application can be produced by preparing a solution containing daptomycin, one or more stabilizers selected from L-arginine, inositol, dextran, meglumine, macrogol, and L-histidine, and optionally additives, and then sterile-filtering the solution, filling it into vials, and lyophilizing it according to standard methods. The solution may be prepared by a method known in the art. For example, daptomycin or the like is dissolved in an aqueous medium at room temperature or with cooling. Dissolution may be performed manually or with a stirrer or the like. The solution may be prepared using a metal container or a non-metallic container such as glass or plastic. Examples of aqueous media include water for injection, distilled water for injection, physiological saline, buffer solution, and replacement fluid (infusion fluid such as electrolyte infusion), with distilled water for injection being preferred. From the viewpoint of drug stability, the pH of the obtained solution is preferably 5.5 to 7.5, more preferably 6.0 to 7.0. The pH can be adjusted using an acid such as hydrochloric acid or an alkali such as sodium hydroxide. A pharma- ceutically acceptable buffer solution may also be used. The aqueous medium may be used in an amount of, for example, 2 ml to 6 ml relative to the total mass of daptomycin. From another perspective, the aqueous medium may be used so that the concentration of daptomycin is 50 w / v % to 275 w / v %. It is preferable to dissolve daptomycin and the like while cooling the aqueous medium, for example, to a temperature of 20° C. or lower, preferably 15° C. or lower. When a freeze-dryer is used in the next step as described below, the cooling may be carried out during transfer to the freeze-dryer and / or within the dryer. Sterile filtration can be performed, for example, using a filter. The obtained solution may be filtered through a filter with a pore size of 0.2 μm to 0.45 μm, for example, a pore size of 0.22 μm. The filter may be, for example, a cartridge filter made of polyvinylidene fluoride. Filtration sterilization includes any process that removes or kills all microbial life forms, including infectious agents (fungi, bacteria, viruses, spore forms, etc.) contained in a liquid. Two or more types of filters with different pore sizes may be used. Typically, a filter with a pore size of 0.22 μm can remove microorganisms as a microfiltration. Sterilization can be performed by methods known in the art. Sterilization can be performed using heat, chemicals, radiation, high pressure, high pressure steam, etc., but it is preferable to adopt a sterilization method that does not involve heat load.

[0013] The lyophilization of the cooled daptomycin-containing solution can be carried out under commonly applied conditions by using a known lyophilization method such as tray lyophilization, spray lyophilization, or vial / syringe lyophilization. For this purpose, it is preferable to use a lyophilizer capable of carrying out these lyophilization methods. In lyophilization, it is usually preferable to dry the lyophilized product so that its water content is 3.0% by mass or less, more preferably 2.0% by mass or less, and even more preferably 1.5% by mass or less.

[0014] The lyophilized preparation is preferably a preparation filled in a container such as a vial or a syringe. In particular, from the viewpoint of easy operation during use, the lyophilized preparation is preferably in the form of, for example, a double-chamber or single-chamber pre-filled syringe. In this case, each preparation preferably contains, for example, 300 mg to 550 mg of daptomycin. Containers such as vials and syringes may be made of either glass or plastic. Of these, glass or olefin-based plastics are preferred. As plastics, cycloolefin polymers, polyethylene and polypropylene are particularly preferred, and cycloolefin polymers and polypropylene are more preferred. When the above-mentioned daptomycin is contained, a container of 10 mL to 20 mL may be used, and a container of 10 mL is preferably used.

[0015] Generally, it is preferable to store the vial, syringe, etc. in a package. It is also preferable to place an oxygen scavenger on the outside of the vial, syringe, etc. The packaging material is preferably one that has low water vapor and / or oxygen permeability. For example, the oxygen permeability is 1 mL / m 2 More preferably, the packaging material has a water vapor transmission rate of 1 g / m2 / day or less and / or a water vapor transmission rate of 1 g / m2 / day or less. Examples of such packaging materials include resin bags having a single-layer structure or a laminate structure of various resins (including aluminum-deposited products) such as polypropylene, polyethylene, polystyrene, polyamide, polycarbonate, polyvinyl chloride, acrylic resin, polyester, and polyolefin.

[0016] The daptomycin-containing lyophilized formulations of the present application may be supplied in the containers described above as sterile, pale yellow to light brown lyophilized cakes (lumps or powders) containing, for example, approximately 500 mg or 350 mg of daptomycin per formulation for intravenous use. The daptomycin-containing lyophilized preparation of the present application can be redissolved in the above-mentioned aqueous medium as necessary and used as an injection solution, etc. In this case, the components and concentrations in these aqueous media can be those used for ordinary injections. From the viewpoint of drug stability, the pH of the reconstituted daptomycin-containing solution is preferably 5.5 to 7.5. The daptomycin-containing freeze-dried preparation of the present application can ensure stability over a long period of time even when stored at room temperature, and can be expected to dissolve quickly when reconstituted. EXAMPLES

[0017] The freeze-dried formulation of the present application will be described in more detail below with reference to examples, although the present invention is not limited to the following examples. Examples and Comparative Examples A drug solution was prepared with the composition shown in Table 1. As the stabilizers in Table 1, L-arginine, inositol, dextran 40, macrogol 4000, histidine, lactose, D-sorbitol, D-mannitol, xylitol and glycine were added in the amounts shown in Table 2. First, daptomycin was dissolved in distilled water for injection (cooled to 10°C) to which sodium hydroxide (appropriate amount) had been added, and then sodium hydroxide solution was added to adjust the pH to 4.7, and then diluted with distilled water for injection to obtain a daptomycin stock solution (daptomycin concentration 110.25 mg / mL). Then, each additive was added and dissolved in the daptomycin stock solution according to the amounts in Table 2, and further hydrochloric acid solution (appropriate amount) or sodium hydroxide solution (appropriate amount) was added to adjust the pH to 6.8 to 7.1, and then diluted with distilled water for injection (daptomycin concentration 91.875 mg / mL). The resulting aqueous solution was sterilized by filtration, and the cooled aqueous solution was filled into a 10 mL glass vial (manufactured by Nipro) so that the vial contained 367.5 mg of daptomycin. The vial was then freeze-dried using a freeze-dryer, stoppered with a rubber stopper, and tightened with an aluminum cap to produce a freeze-dried formulation. [Table 1] [Table 2] As a reference example, a lyophilized preparation was produced in the same manner as above except that the stabilizer was not included. The obtained lyophilized preparation was stored at 60°C for 21 days, after which the increase in the total amount of related substances was measured. The results are shown in Table 3. In Table 3, the increase in the amount of lyophilized preparation produced without using any additives was set to 1, and the values ​​were calculated according to the following formula. (1) Calculation of the increase (each additive "total amount of related substances at 60°C for 21 days" - each additive "amount at the start") / (no additive "total amount of related substances at 60°C for 21 days" - no additive "amount at the start") [Table 3]

[0018] (2) Measurement method for total related substances The lyophilized preparation obtained in the Examples or Comparative Examples was redissolved in 7 mL of water. This solution was diluted 50-fold with a water / acetonitrile mixture (2:1), and 10 μL of the solution was used in the test to measure the change over time in the total related substances. <Detection conditions> Equipment name: High-performance liquid chromatograph Detector: Ultraviolet spectrophotometer (wavelength: 221 nm) Column: 250 x 4.6 mm I.D. octyl silica gel Column temperature: constant temperature around 30℃ Mobile phase A: 0.34% ammonium phosphate buffer (pH 3.1) Mobile phase B: Acetonitrile Delivery of mobile phase: The concentration gradient was controlled by changing the mixing ratio of mobile phase A and mobile phase B as follows: JPEG0007582205000004.jpg52144 Flow rate: 1mL / min. Under the above detection conditions, the peak area of ​​each sample was measured by automatic integration, and the percentage of the total related substances was obtained.

[0019] Among the additives shown in Table 2, L-arginine, inositol, dextran 40, and L-histidine were confirmed to significantly suppress the increase in both total related substances and lactone hydrolysates compared to the freeze-dried preparation produced without additives. Macrogol 4000 was confirmed to significantly suppress the increase in total related substances compared to the freeze-dried preparation produced without additives.

[0020] Test Example Of the above stabilizers, L-arginine was found to have the most significant effect, and the amounts added were set to 350 mg, 400 mg, and 500 mg to produce freeze-dried preparations. For the samples, L-arginine was dissolved in a hydrochloric acid solution at 10°C, followed by dissolving daptomycin and adjusting the pH to 6.8 with a hydrochloric acid solution (sodium hydroxide was not used). Other than that, the freeze-dried preparations were produced in the same manner as in the previous examples. As a comparative example, a freeze-dried preparation was produced by adding 524 mg of sucrose instead of L-arginine (since sucrose was described in Patent Document 1: JP-T-2013-511557). However, a sodium hydroxide solution was used instead of a hydrochloric acid solution, and the pH was adjusted to 7.0. The freeze-dried preparation thus obtained was stored at 60° C. for 21 days, after which the increase in the total amount of related substances and the time required for reconstitution were evaluated. The results are shown in Table 4, and the evaluation results of the increase in the total amount of related substances are shown in FIG. [Table 4] As is clear from Table 4 and Figure 1, it was confirmed that when L-arginine is used as a stabilizer in a solution containing daptomycin, the generation of total related substances can be suppressed and the increase in total related substances over time can be prevented with an increase in the amount of L-arginine added. It was also confirmed that the addition of L-arginine allows the daptomycin-containing lyophilized preparation to be redissolved relatively quickly. [Industrial Applicability]

[0021] The daptomycin-containing lyophilized formulations of the present application can be stabilized to the extent that they can be stored at room temperature.

Claims

1. Daptomycin, and a stabilizer which is L-arginine, The content of L-arginine is 350 mg to 400 mg per 367.5 mg of daptomycin, and The freeze-dried preparation contains no amino acids other than L-arginine.

2. The lyophilized formulation of claim 1, which does not contain a calcium source.

3. 3. The stable lyophilized preparation according to claim 1 or 2, wherein the pH of the preparation when dissolved with water for injection is 5.5 to 7.5.

Citation Information

Patent Citations

  • Daptomycin freeze-dried powder injection and preparation process thereof

    CN106943587A

  • Daptomycin and composition of salts of Daptomycin

    CN110339341A

  • Daptomycin freeze-dried preparation for injection and preparing method

    CN1616083A

  • Lipopeptide composition and related method

    JP2013511557A

  • Daptomycin formulations

    WO2019043008A1